Medicamen Biotech Limited — Others, 28-03-2025: Shareholders meeting

Medicamen Biotech Limited has announced a board meeting to discuss significant progress in its strategic expansion into regulated markets, specifically obtaining approvals from the EU and USFDA for manufacturing operations. This positions the company to tap into emerging geographies, with ongoing applications for certifications in Canada and Australia, expected within six months. The release of a Vision 2030 document outlines Medicamen's achievements and future goals, indicating a robust growth trajectory. This expansion is likely to enhance market presence and bolster investor confidence, promoting a positive outlook as the company establishes global partnerships for product marketing.